H3 Biomedicine Inc-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8014197)
◆英語タイトル:H3 Biomedicine Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014197
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:26
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
H3 Biomedicine Inc (H3 Biomedicine), a subsidiary of Eisai Co Ltd is a biopharmaceutical company that offers therapies. The company concentrates on discovery and early development of novel, targeted anti-cancer compounds. Its products include small-molecule drugs that are developed by utilizing synthetic chemistry approaches and advanced cell-based screening methods. H3 Biomedicine concentrates on scientific approaches and develops new platforms for multiple drug candidate programs. The company leverages the external and internal cumulative investment in cancer genomics to identify therapeutic targets and biomarkers. It operates in the areas of genomics, tumor biology, bioinformatics and innovative synthetic organic chemistry. The company operates through other biotechnology companies for research and development activities and advance cancer treatment options. H3 Biomedicine is headquartered in Cambridge, Massachusetts, the US.

H3 Biomedicine Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
H3 Biomedicine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
H3 Biomedicine Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
H3 Biomedicine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
H3 Biomedicine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
H3 Biomedicine Inc, Medical Devices Deals, 2011 to YTD 2017 9
H3 Biomedicine Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
H3 Biomedicine Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Cancer Genetics Partners with H3 Biomedicine 11
Foundation Medicine Extends its Co-Development Agreement with H3 Biomedicine 12
H3 Biomedicine Extends Agreement with Selvita 13
H3 Biomedicine And BGI Enter Into Agreement To Develop And Share Cancer Genomic Sequencing Data 14
H3 Biomedicine Enters Into Agreement With Sage Bionetworks For Cancer-Genomics Research 15
Horizon Discovery Enters Into Co-Development Agreement With H3 Biomedicine 16
Licensing Agreements 17
Compendia Bioscience Enters Into Licensing Agreement With H3 Biomedicine 17
H3 Biomedicine Inc – Key Competitors 18
H3 Biomedicine Inc – Key Employees 19
H3 Biomedicine Inc – Locations And Subsidiaries 20
Head Office 20
Recent Developments 21
Corporate Communications 21
Feb 20, 2017: H3 Biomedicine Announces Appointment of Peter G. Smith, Ph. D., to Chief Scientific Officer 21
Jun 01, 2016: H3 Biomedicine Announces Appointment of Tarek Sahmoud as Chief Medical Officer 22
Product News 23
03/09/2017: H3 Biomedicine to Present on H3B-6545 at 2017 American Association of Cancer Research Annual Meeting 23
Product Approvals 24
May 11, 2016: H3 Biomedicine Receives FDA Acceptance for Investigational New Drug Application 24
Clinical Trials 25
Jul 24, 2017: H3 Biomedicine and University of British Columbia Scientists Report Preclinical Data Describing Immune Evasion Mechanism in Muscle-Invasive Bladder Cancer 25
Appendix 26
Methodology 26
About GlobalData 26
Contact Us 26
Disclaimer 26

List of Tables
H3 Biomedicine Inc, Pharmaceuticals & Healthcare, Key Facts 2
H3 Biomedicine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
H3 Biomedicine Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
H3 Biomedicine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
H3 Biomedicine Inc, Deals By Therapy Area, 2011 to YTD 2017 8
H3 Biomedicine Inc, Medical Devices Deals, 2011 to YTD 2017 9
H3 Biomedicine Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Cancer Genetics Partners with H3 Biomedicine 11
Foundation Medicine Extends its Co-Development Agreement with H3 Biomedicine 12
H3 Biomedicine Extends Agreement with Selvita 13
H3 Biomedicine And BGI Enter Into Agreement To Develop And Share Cancer Genomic Sequencing Data 14
H3 Biomedicine Enters Into Agreement With Sage Bionetworks For Cancer-Genomics Research 15
Horizon Discovery Enters Into Co-Development Agreement With H3 Biomedicine 16
Compendia Bioscience Enters Into Licensing Agreement With H3 Biomedicine 17
H3 Biomedicine Inc, Key Competitors 18
H3 Biomedicine Inc, Key Employees 19

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ H3 Biomedicine Inc-製薬・医療分野:企業M&A・提携分析(H3 Biomedicine Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆